Sharp, a leading contract development and manufacturing organization (CDMO), has announced a significant investment exceeding €20 million aimed at expanding its injectable packaging, assembly, and cold-chain storage capacities across its European facilities. This strategic expansion targets two key sites: Hamont-Achel in Belgium and Heerenveen in the Netherlands, directly addressing the surging demand in the injectables market, which includes critical formats such as autoinjectors, pen devices, pre-filled syringes, and vials.

At the Hamont-Achel facility in Belgium, the investment will quadruple the existing cold-chain warehouse capacity and double the ambient storage space. A new syringe assembly and blister packaging suite is being introduced, complemented by additional device assembly and packaging lines. To enhance production efficiency, collaborative robot technology—commonly known as cobots—has been integrated into the pre-filled syringe and autoinjector production lines. This automation not only streamlines operations but also aligns with broader industry trends toward laboratory automation and robotics in pharmaceutical manufacturing. Furthermore, the site has been upgraded with a carport solar system, projected to supply approximately 50% of the facility's electricity needs by mid-2026. This initiative underscores Sharp's commitment to environment recycle and water management, as well as sustainability goals, while supporting the increased operational demands driven by client needs in pharmaceutical packaging machinery and cold chain storage and distribution.

In the Netherlands, the Heerenveen facility will see an expansion of its GMP-compliant production capacity, including the addition of two new Grade D packaging suites. These upgrades will facilitate new programs for syringe assembly, packaging, and vial packaging, with full operations expected to come online throughout 2026. This development strengthens Sharp's position in pharmaceutical process machinery and contract packaging services, enabling faster support for client drug launches across Europe.

This €20 million European investment forms part of a larger $100 million global commitment announced by Sharp in November 2025, highlighting the company's proactive approach to scaling operations amid growing pharmaceutical outsourcing demands. Robert O’Beirn, Managing Director of Sharp Clinical & Sharp Europe, emphasized the facilities' established reputation for delivering complex packaging services for injectable drug formats. The expansions ensure Sharp can meet the rigorous requirements of pharmaceutical quality assurance, validation, and pharmaceutical materials handling, while enhancing supply chain resilience in the region.

For pharmaceutical executives and CRO/CMO leaders, this move exemplifies how CDMOs are investing in infrastructure to handle specialized formats like pre-filled syringes and autoinjectors, which are pivotal in biologics and advanced therapies. The incorporation of cobots represents a leap in laboratory automation and robotics, reducing manual intervention, improving throughput, and minimizing errors in cleanroom environments. The solar integration at Hamont-Achel also positions Sharp as a leader in sustainable pharmaceutical manufacturing equipment, potentially setting a benchmark for fixtures and fittings in eco-friendly cleanroom solutions.

Looking ahead, these enhancements will bolster Europe's pharmaceutical supply chain solutions by increasing local capacity for contract manufacturing and packaging, reducing reliance on distant suppliers, and mitigating risks associated with global disruptions. Procurement professionals will benefit from expanded cold-chain capabilities, crucial for temperature-sensitive injectables. Manufacturing managers can anticipate improved scalability and efficiency, with the new suites supporting higher volumes without compromising GMP standards.

In the context of ongoing EU regulatory evolutions, such as the Critical Medicines Act and revised pharmaceutical legislation, investments like Sharp's are vital for ensuring security of supply for essential medicines. By diversifying manufacturing within the EU, Sharp contributes to broader goals of pharmaceutical self-sufficiency. R&D heads and technology vendors should note the focus on advanced assembly technologies, which could integrate with emerging pharmaceutical instrumentation and controls for smarter production lines.

Overall, Sharp's expansion not only responds to immediate market pressures but also future-proofs its operations, reinforcing its role in pharmaceutical outsourcing and contract services across Europe. This development signals confidence in the injectables sector's growth trajectory, driven by innovations in biotechnology and pharmaceutical formulations requiring precise packaging solutions.